Oncology

Gene expression panel could help breast cancer patients with a low risk of recurrence avoid unnecessary chemotherapy

A genetic test for prostate cancer risk could be used in screening, and improve the diagnostic value of PSA

Keith Miller is Director and co-founder of CADQAS (Cancer Diagnostic Quality Assurance Services), a not-for-profit community interest company hosted by Poundbury Cancer Institute (PCI).

Christopher Hudson is Director of Tissue Diagnostics UK and Ireland at Roche, the multinational life sciences company that supports the Poundbury Cancer Institute through funding and research collaboration.

A new device, the Cytosponge, could pair with biomarker testing to offer an effective, low-cost way to diagnose and stratify Barrett’s esophagus

Tumor-activated DNA minicircles offer a potential solution for cancer detection, treatment, or both.

Poundbury Cancer Institute aims to put pathology at the forefront of cancer research, and bring industry, national healthcare service and quality assurance together to expand the use of companion diagnostics and important biological markers.

At the Poundbury Cancer Center, pathology, business and quality assurance are uniting to create a cutting-edge home for companion diagnostics.

Predictive test shows promise in catching breast cancer relapse, but caution urged over sensationalist headlines

There’s a whole new world of molecular diagnostics out there. Why has innovation been restricted?